Nephrol Dial Transplant (2002) 17: 871-878
© 2002 European Renal Association-European Dialysis and Transplant Association
Daily haemodialysis improves indices of protein glycation
1 Department of Internal Medicine, Section of Applied and Clinical Biochemistry, University of Perugia, and 2 Nephrology–Dialysis Unit, ‘R. Silvestrini’ Hospital, Perugia, Italy
Background. Advanced glycation end-products (AGEs) accumulate in uraemia, regardless of hyperglycaemic conditions, and may contribute to the onset of some long-term complications, such as atherosclerosis, amyloidosis, and neurodegenerative processes. In this study, we compare a daily with a standard 3 times/week dialysis rhythm (DHD and SHD, respectively) in correcting some protein glycation indices in end-stage renal disease (ESRD) patients.
Methods. Twenty-one normoglycaemic and 11 diabetic patients on chronic haemodialysis (HD) with low-flux dialysers were studied in a prospective protocol to compare two different dialysis schedules, namely: 4 h, 3 times/week (SHD) and 2 h, 6 times/week (DHD). The patients were studied before and after 6 months of DHD. To further check the effect of DHD on glycation parameters, 4 normoglycaemic HD patients were studied in a third step in which they returned for 3 months to the SHD rhythm. Also, 11 chronic renal failure (CRF) patients not yet on HD and 11 age- and sex-matched healthy controls were studied. A new HPLC method was used to measure the following glycation indexes on plasma: the early product furosine and the advanced products protein-bound and free pentosidine, and two heterogeneous classes of low molecular mass (LMM) AGE peptides.
Results. All the parameters studied showed an accumulation that worsened with the progression of renal failure (controls <CRF <HD). Diabetic patients on SHD showed similar levels of glycation indexes as non-diabetic patients, except for the early product furosine that was notably higher. The shift from SHD to DHD was effective in lowering the concentration of all the glycation parameters measured, both in non-diabetic and diabetic patients. In the total HD population, LMM-AGEs (MM range of approx. 1.5–6.0 kDa) detected at 385 nm emission was lowered by 56% (P<0.001) and LMM-AGEs detected at 440 nm emission and furosine decreased by 23 and 19%, (P
0.001 and <0.01, respectively). All these three classes of compounds reached concentrations comparable with those observed in the CRF patients, even if remaining above the control range. The levels of both free and protein-bound pentosidine after DHD decreased by 34% (P<0.001) and 22% (P0.05), respectively. The return for 3 months to SHD in four non-diabetic DHD patients led to a trend toward an increase in all five glycation parameters.
Conclusions. This study demonstrates for the first time that a DHD regimen can effectively lower the mean levels of glycation-related substances observed in SHD. Therefore, DHD can provide a better control of AGE produced in ESRD. This could result in a lower incidence of long-term effects of AGE accumulation in HD.
Keywords: AGEs; furosine; daily haemodialysis; pentosidine; protein glycation; uraemic toxins
Correspondence and offprint requests to: Francesco Galli, PhD, Department of Internal Medicine, Section of Applied and Clinical Biochemistry, University of Perugia, Via del Giochetto, I-06100 Perugia, Italy. Email: f.galli{at}unipg.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Punal, L. V. Lema, D. Sanhez-Guisande, and A. Ruano-Ravina Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2634 - 2646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Galli Protein damage and inflammation in uraemia and dialysis patients Nephrol. Dial. Transplant., July 1, 2007; 22(suppl_5): v20 - v36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Nazratun, A A Mahmood, U R Kuppusamy, T S. Ahmad, and S Y Tan Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients Vascular Medicine, November 1, 2006; 11(4): 245 - 250. [Abstract] [PDF]
|
|
|
|
|
|
F. Locatelli, U. Buoncristiani, B. Canaud, H. Kohler, T. Petitclerc, and P. Zucchelli Dialysis dose and frequency Nephrol. Dial. Transplant., February 1, 2005; 20(2): 285 - 296. [Abstract] [Full Text] [PDF]
|
|